| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Cancer immunotherapy with dendritic cells (DCs) and low-dose chemotherapy is novel therapeutic strategy for improvement of survival rate in recurrent head and neck cancer (HNC) patients. We developed this protocol, and followed by examination of safety and clinical benefits. DCs were collected from HNC patients by leukoapheresis and stimulated by GM-CSF and IL-4 for five days in cell-processing center. Rates of immature collection were 1.08% to 16.7%. There were no adverse effects caused by cyclophosphamide and docetaxel in 5 recurrent HNC patients. However, administration of OK432 after injection of DCs into tumor tissues significantly caused febrile symptoms (BT > 38.5℃) in 4 patients. Among these patients, septic shock was happened in one patient. Among 3 patients who accomplished planned therapeutic schedules of DCs immunotherapy with low-dose chemotherapy, one patient was regarded as stable disease, while two patients were regarded as progressive diseases.
|
